SEDLÁKOVÁ, Veronika, Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI, Irene GUZMAN-SOTO, Marc RUEL, Erik SUURONEN a Emilio I ALARCON. Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022. ACTA BIOMATERIALIA. London: ELSEVIER SCI LTD, 2024, roč. 180, May 2024, s. 61-81. ISSN 1742-7061. Dostupné z: https://dx.doi.org/10.1016/j.actbio.2024.04.008.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022
Autoři SEDLÁKOVÁ, Veronika (203 Česká republika, domácí), Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI, Irene GUZMAN-SOTO, Marc RUEL, Erik SUURONEN a Emilio I ALARCON.
Vydání ACTA BIOMATERIALIA, London, ELSEVIER SCI LTD, 2024, 1742-7061.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 9.700 v roce 2022
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.actbio.2024.04.008
UT WoS 001240708500001
Klíčová slova anglicky Heart disease; Clinical trial; Scoping review; Multi-database searching
Štítky 14110517, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 2. 7. 2024 09:31.
Anotace
A plethora of biomaterials for heart repair are being tested worldwide for potential clinical application. These therapeutics aim to enhance the quality of life of patients with heart disease using various methods to improve cardiac function. Despite the myriad of therapeutics tested, only a minority of these studied biomaterials have entered clinical trials. This rapid scoping review aims to analyze literature available from 2012 to 2022 with a focus on clinical trials using biomaterials for direct cardiac repair, i.e., where the intended function of the biomaterial is to enhance the repair of the endocardium, myocardium, epicardium or pericardium. This review included neither biomaterials related to stents and valve repair nor biomaterials serving as vehicles for the delivery of drugs. Surprisingly, the literature search revealed that only 8 different biomaterials mentioned in 23 different studies out of 7038 documents (journal articles, conference abstracts or clinical trial entries) have been tested in clinical trials since 2012. All of these, intended to treat various forms of ischaemic heart disease (heart failure, myocardial infarction), were of natural origin and most used direct injections as their delivery method. This review thus reveals notable gaps between groups of biomaterials tested pre-clinically and clinically.
VytisknoutZobrazeno: 13. 7. 2024 10:03